Body Cavity–Based Lymphoma in a Country with Low Human Immunodeficiency Virus Prevalence: A Series of 17 Cases from the Consortium for Improving Survival of Lymphoma
- Author:
Junghoon SHIN
1
;
Young Hyeh KO
;
Sung Yong OH
;
Dok Hyun YOON
;
Jeong Ok LEE
;
Jin Seok KIM
;
Yong PARK
;
Ho Jin SHIN
;
Seok Jin KIM
;
Jong Ho WON
;
Sung Soo YOON
;
Won Seog KIM
;
Youngil KOH
;
Author Information
- Publication Type:Original Article
- Keywords: Body cavity-based lymphoma; Primary effusion lymphoma; Human herpesvirus 8; Human immunodeficiency virus; Immunophenotype
- MeSH: Drug Therapy; Herpesvirus 8, Human; HIV; Humans; Korea; Lymphoma; Lymphoma, Primary Effusion; Prevalence; Retrospective Studies; Watchful Waiting
- From:Cancer Research and Treatment 2019;51(4):1302-1312
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: Primary effusion lymphoma (PEL) is a type of body cavity–based lymphoma (BCBL). Most patients with PEL are severely immunocompromised and seropositive for human immunodeficiency virus (HIV). We investigated the distinctive clinicopathologic characteristics of BCBL in a country with low HIV burden. MATERIALS AND METHODS: We retrospectively collected data on the clinicopathologic characteristics, treatments, and outcomes of 17 consecutive patients with BCBL at nine institutions in Korea. RESULTS: Latency-associated nuclear antigen 1 (LANA1) immunostaining indicated that six patients had PEL, six patients had human herpesvirus 8 (HHV8)-unrelated BCBL, and five patients had HHV8-unknown BCBL. The patients with PEL exhibited no evidence of immunodeficiency except for one who was HIV positive. One (20%) and four (80%) patients with PEL and six (100%) and zero (0%) patients with HHV8-unrelated BCBL were positive for CD20 and CD30 expression, respectively. The two patients with PEL (one HIV-positive and one HIV-negative patient) with the lowest proliferation activity as assessed by the Ki-67 labeling index survived for > 1 and > 4 years without chemotherapy, respectively, in contrast to the PEL cases in the literature, which mostly showed a high proliferation index and poor survival. CONCLUSION: PEL mostly occurred in ostensibly immunocompetent individuals and had a favorable outcome in Korea. A watchful waiting approach may be applicable for managing HIV-seronegative patients with PEL with a low Ki-67 labeling index. A possible trend was detected among LANA1, CD20, and CD30 expression in BCBL.
